Indegene Ltd

AI

Indegene Ltd

₹ 568 0.19%
21 Aug - close price
About

Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]

Key Points

Business Overview [1]
The company is a strategic operating partner to the global life sciences industry, supporting commercial, medical, R&D, and safety operations across the product lifecycle. It combines deep life sciences expertise with AI-enabled platforms, data analytics, and governed operating models, servicing the world’s top 20 biopharma companies. Its capabilities span five key areas: Discovery & Evidence, Regulatory & Compliance, Commercial Launch, Content & Engagement, and Patient & Outcomes.

  • Market Cap 13,679 Cr.
  • Current Price 568
  • High / Low 597 / 414
  • Stock P/E 32.9
  • Book Value 130
  • Dividend Yield 0.40 %
  • ROCE 18.8 %
  • ROE 14.4 %
  • Face Value 2.00

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
608 636 673 673 676 687 720 756 761 804 942 1,003 1,063
511 515 524 534 548 561 589 608 606 664 783 840 889
Operating Profit 97 121 149 139 129 126 132 148 155 141 160 164 174
OPM % 16% 19% 22% 21% 19% 18% 18% 20% 20% 17% 17% 16% 16%
28 12 13 26 22 21 38 26 22 20 19 -10 29
Interest 13 12 12 12 12 4 3 3 4 4 5 7 6
Depreciation 20 20 18 18 20 19 20 21 22 23 40 42 44
Profit before tax 92 101 132 134 120 124 146 149 152 133 135 105 153
Tax % 26% 25% 25% 29% 27% 26% 25% 21% 23% 23% 24% 24% 24%
68 75 99 95 88 92 110 118 116 102 103 80 116
EPS in Rs 3.08 3.38 4.45 4.26 3.67 3.83 4.58 4.90 4.85 4.25 4.28 3.31 4.82
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
553 643 966 1,665 2,306 2,590 2,839 3,510 3,813
511 499 736 1,378 1,910 2,084 2,292 2,892 3,175
Operating Profit 42 144 230 287 396 505 548 619 638
OPM % 8% 22% 24% 17% 17% 20% 19% 18% 17%
7 -102 -3 -21 58 79 94 52 59
Interest 6 9 7 6 31 49 22 19 22
Depreciation 17 19 26 33 60 76 80 126 149
Profit before tax 26 14 195 226 363 459 539 525 526
Tax % 45% 191% 23% 28% 27% 27% 25% 24%
14 -12 149 163 266 337 407 401 401
EPS in Rs 89.98 -40.20 951.96 937.73 11.99 15.14 16.95 16.65 16.66
Dividend Payout % 0% 0% 0% 0% 0% 0% 12% 13%
Compounded Sales Growth
10 Years: %
5 Years: 29%
3 Years: 15%
TTM: 30%
Compounded Profit Growth
10 Years: %
5 Years: 23%
3 Years: 16%
TTM: -4%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -1%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 19%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.31 0.31 0.31 0.35 44 44 48 48
Reserves 73 -105 324 764 1,020 1,385 2,568 3,091
147 483 51 66 502 490 102 144
108 222 220 524 638 627 609 1,337
Total Liabilities 329 600 596 1,353 2,204 2,546 3,326 4,620
104 119 86 138 664 646 678 1,812
CWIP 0 0 0 0 0 0 4 12
Investments 0 13 0 120 614 796 1,290 1,100
225 468 510 1,096 926 1,103 1,355 1,697
Total Assets 329 600 596 1,353 2,204 2,546 3,326 4,620

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
65 22 172 297 130 508 442 651
-18 -16 -81 -158 -896 -326 -677 -508
-21 136 -132 233 333 -66 288 -83
Net Cash Flow 25 143 -40 373 -433 115 52 60
Free Cash Flow 48 16 151 272 111 497 412 606
CFO/OP 196% 34% 96% 128% 60% 125% 110% 129%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 60 127 108 97 102 91 97 102
Inventory Days
Days Payable
Cash Conversion Cycle 60 127 108 97 102 91 97 102
Working Capital Days -7 -5 45 11 41 27 39 5
ROCE % 37% 55% 46% 33% 29% 25% 19%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
$1M+ Clients
Count

Log in to view insights

Please log in to see hidden values.

Login
Active Client Relationships
Count
Total Employees
Count
$25M+ Strategic Clients
Count
Top 20 Customer Revenue
INR Mn
Revenue per Employee
USD
Net Revenue Retention
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

11 Recently
Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
3.79% 4.82% 5.03% 5.24% 10.04% 11.30% 11.48% 10.27% 9.92%
3.84% 3.17% 3.99% 4.96% 7.20% 6.95% 8.06% 8.29% 8.74%
92.38% 92.01% 91.01% 89.80% 82.75% 81.74% 80.44% 81.43% 81.34%
No. of Shareholders 2,03,5991,51,4401,53,7891,44,7081,51,9971,51,8091,47,1821,42,1191,38,533

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls